ASO Author Reflections: A Simplified Classification System for In-Transit Melanoma Metastases
Sofia Breeze, Clare Peterson, Marc Moncrieff
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCutaneous Melanoma Detection and Management · AI in cancer detection · Melanoma and MAPK Pathways
Past
In-transit metastases are a challenging manifestation of cutaneous melanoma and are frequently encountered in modern practice.^1^ Unlike nodal or distant relapse, in-transit disease usually behaves as a chronic relapsing and evolving condition. Patients may experience a gradual increase in disease burden over time yet remain within the same AJCC stage.^2^ This disconnect between disease biology and staging creates uncertainty about prognosis and contributes to variation in clinical management. Decisions about whether to continue loco-regional control strategies or escalate to systemic therapy are often based on subjective interpretation and institutional bias, rather than objective criteria. Despite therapeutic advances, there remains no dedicated framework to stratify risk or inform treatment sequencing in patients with in-transit metastases.
Present
Our current study of 142 patients,^3^ treated within a quaternary-referral melanoma service, identified key clinical features that reflect aggressive in-transit disease behaviour. Patients with more than two lesions and/or those larger than 30 mm at initial presentation, or a short interval between treatment of the primary melanoma and development of in-transit disease (18 months or less) experienced significantly worse melanoma-specific survival. Synchronous nodal disease also correlated with poor distant metastasis-free survival. These findings suggest that not all in-transit disease is biologically equivalent, nor is the patient’s response to the disease and its subsequent treatment, and that early disease dynamics provide valuable prognostic information. By defining clinically relevant thresholds, our work offers a step towards classifying patients according to disease risk rather than anatomical pattern alone.
Future
We are hopeful that these results provide a foundation for the development of a simplified, clinically meaningful classification system for in-transit melanoma. Validation in external cohorts is now required, alongside further exploration of molecular and immune biomarkers to refine prognostic accuracy.^4^ Ultimately, a dedicated risk stratification framework could support personalised treatment strategies, consistency in reporting outcomes and rational stratification in future clinical trials.